BACKGROUND: @entity2752 has been approved for treatment of locally advanced or metastatic @entity1491 ( @entity1491 ). Its use for postirradiation multiple BCCs has not yet been reported. OBJECTIVE: We sought to investigate the effectiveness and safety of vismodegib for the treatment of recurrent radiation-induced multiple BCCs. METHODS: @entity1 with recurrent multiple BCCs treated with vismodegib and a history of exposure to radiation treatment were followed up prospectively at a tertiary dermato-oncology clinic during a 19-month period. RESULTS: Eight @entity1 met the study criteria. Mean duration of vismodegib treatment was 29  weeks (range 2-52), and of follow-up, 34  weeks (range 8-64). Drug tolerability was acceptable in 7 @entity1 , of whom 4 showed a partial response and 3 had stable disease. In 1 @entity1 , @entity2752 was discontinued soon after its initiation because of a severe drug-induced @entity203 . LIMITATIONS: Small sample size and short follow-up time are limitations. CONCLUSION: Vismodegib holds promise for the treatment of the subpopulation of @entity1 with radiation-induced multiple BCCs in whom therapeutic options have so far been limited.

Vismodegib for radiation-induced XXXX (BCCs) of the scalp.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity203 :: ('MESH:D003875', 'Disease') :: ['eruption'] @entity2752 :: ('MESH:C538724', 'Chemical') :: ['vismodegib', 'Vismodegib'] @entity1491 :: ('MESH:D002280', 'Disease') :: ['basal cell carcinoma', 'BCC']
@entity1491 :: (MESH:D002280,Disease) :: ['multiple basal cell carcinomas']
